Related Experiment Video
Updated: May 14, 2026
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Neurocognitive dysfunction in old diabetes: management and treatment
1Department Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. umegaki@med.nagoya-u.ac.jp
Advances in Experimental Medicine and Biology
|February 9, 2013
Summary
Type 2 diabetes mellitus increases dementia risk, but the exact causes are unknown. Careful blood sugar management is key for cognitive health in diabetics, avoiding hypoglycemia.
Area of Science:
- Gerontology
- Neurology
- Endocrinology
Background:
- Type 2 diabetes mellitus (T2DM) is a recognized risk factor for cognitive decline and dementia.
- The precise mechanisms linking T2DM to cognitive impairment remain incompletely understood, suggesting a multifactorial etiology.
Purpose of the Study:
- To explore the association between T2DM and cognitive decline.
- To highlight the importance of metabolic control in managing cognitive function in elderly T2DM patients.
- To emphasize the need for careful glycaemic management, avoiding hypoglycemia, in T2DM patients with cognitive impairment.
Main Methods:
- This study is a review of current literature on T2DM and cognitive decline.
- It synthesizes findings on the impact of metabolic control on cognitive function in T2DM.
- It discusses challenges in managing diabetes in patients with dementia.
Main Results:
- Good metabolic control in elderly T2DM patients may prevent or slow cognitive decline.
- Hypoglycemia must be strictly avoided in T2DM patients with cognitive impairment.
- Diabetic patients with dementia often experience loss of self-care ability and behavioral symptoms, complicating diabetes management.
Conclusions:
- Effective glycaemic control is crucial for preserving cognitive function in individuals with T2DM.
- Further research is essential to understand the T2DM-dementia link and optimize management strategies for this growing population.
- Addressing behavioral symptoms and depressive mood is vital for comprehensive care.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...